Navigation Links
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
Date:10/7/2008

rmally increased intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through inhibitory, direct effects on gastrointestinal associated lymphoid tissue. Larazotide acetate is a non-absorbed peptide which improves mucosal barrier function by inhibiting cytoskeletal reorganization and tight junction disassembly. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of Celiac disease, and is also being evaluated for the treatment of Crohn's Disease. Results of the Company's first study in patients with celiac disease are available online at: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413.x

For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Alba Therapeutics Corporation

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies to treat auto-immune, immune mediated and inflammatory diseases and is located in Baltimore, Maryland. Alba's technology platform is based upon a key pathway that regulates the assembly and disassembly of tight junctions in cell barriers throughout the body. As a result of its unique technology platform, Alba is a leader in mucosal biology and has developed a pipeline of innovative therapeutic candidates that has the potential to modify the course of disease and significantly improve upon existing treatments for a wide range of diseases such as Celiac disease, Crohn's disease, and Asthma/COPD or acute lung injury.

Media: Mariesa Kemble


'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
2. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
3. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
4. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
5. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
6. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
7. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
10. Tobira Therapeutics Inc. Receives US Patent for TBR-652
11. MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014  IBM (NYSE: ... Deutsches Elektronen-Synchrotron ( DESY ), a leading national research ... up management and storage of massive volumes of x-ray ... architecture based on IBM software defined technology can handle ... peak performance and help scientists worldwide gain faster insights ...
(Date:8/21/2014)... CINCINNATI , Aug. 21, 2014  Seventy-one percent of ... as OxyContin is a serious public health and safety issue ... findings from a survey released today by Repass & Partners, ... "Americans understand the severity of the prescription ... make progress with this very serious health situation facing our ...
(Date:8/21/2014)... , August 21, 2014 ... BreedIT Ltd., the exclusive worldwide license holder and ... plant breeders and researchers, today is pleased to ... venture with Seach Ltd, a leading Israeli medical ... research and develop new breeds of medical Cannabis ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4
... PEGINTRON(TM) clinical studies address key questions in the ... Schering-Plough Corporation (NYSE: SGP ) today ... (peginterferon alfa-2b) clinical studies address longstanding questions in ... insights. The results of the studies, involving ...
... as many injections, in two pivotal Phase 3 ... endpoint of sustained virologic response comparable to Pegasys ... had comparable rates of serious and/or severe adverse ... peginterferon alfa-2a -- Submission of global marketing applications ...
Cached Medicine Technology:Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 9Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 10Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 11Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 2Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 3Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 4Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 5Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 6Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 7Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C 8
(Date:8/22/2014)... 2014 Aid in Recovery, a full ... today regarding a recent bill introduced in ... a current legislator and retired police general. In House ... related offenders, rather than imprisonment. Aid in Recovery points ... solution for the drug addiction epidemic. , The bill, ...
(Date:8/21/2014)... August 22, 2014 Os-Monitor.com, an ... unveiled its new employee monitoring software collection ( ... has also announced that all these high end ... , With the tendency of improving productivity, the ... efficiency than before. Thus, employee and network monitoring ...
(Date:8/21/2014)... Recently, Top10BestSEOHosting.com has compared many professional ... is one of the most reliable suppliers for webmasters ... has been a boom in websites in recent years, ... in the number of web hosting companies that offer ... , HostMonster has been providing hosting solutions to thousands ...
(Date:8/21/2014)... a distinguished garment supplier, has updated its product line with ... From today until August 31, all clients can enjoy a ... shopping at the company’s online store. , All of ... quality standards; they are guaranteed to be fashionable and comfortable. ... also access the other cheap items in its online store, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
Breaking Medicine News(10 mins):Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 2Health News:Proposed Legislature in the Philippines Highlights the Need for Rehabilitation, Not Incarceration, for Drug Users, Says Aid in Recovery 3Health News:New Employee Monitoring Software Collection Unveiled By Os-Monitor.com 2Health News:Best SEO Hosting Suppliers in the Global Market Recommended by Top10BestSEOHosting.com 2Health News:Charming Girls’ Casual Dresses Now Released by Distinguished Garment Company Skmen.com 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... that only hormones can reduce hot flashes effectively. The good news ... but also safely. , ... Ann Arbor, MI (PRWEB) July 21, 2008 ... experts are endlessly debating merits of synthetic or bio-identical hormones. Too much ...
... step in understanding how the nervous system and the immune system interact, ... anatomical path through which the brain and the spleen communicate. , ... ... understanding how the nervous system and the immune system interact, scientists at ...
... CHICAGO -- Olympic athletes aren,t the only ones who ... in Beijing. The dirty air may trigger serious cardiovascular ... pulmonary medicine and critical care at Northwestern University,s Feinberg ... risk groups, breathing high levels of pollution can cause ...
... Kennedy DSc, Dean of Tufts University,s Gerald J. and ... announced the 3rd Annual Friedman School Symposium, a conference ... industry, policy-makers, academics and thought leaders in the coming ... 24th to 26th, 2008. , Fifteen experts will present ...
... less, , , MONDAY, July 21 (HealthDay News) -- With the ... are likely the next biggest expense in your family,s budget. ... of the average Americans income. , During all of ... just the first five months of 2008, food prices jumped ...
... July 21 The Institute for Advanced Medical,Education ... Breast,Biopsy, its much-awaited online CME program. Produced in ... community, this course offers the 3 CME,credits required ... Breast Biopsy is a multimedia course,available online at ...
Cached Medicine News:Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 2Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 3Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 3Health News:Beijing pollution may trigger heart attacks, strokes 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:Stretch That Grocery List in Lean Times 2Health News:Stretch That Grocery List in Lean Times 3
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 900 high frequency desiccator forever removes the need to go through a tedious multi-step process to change from low to high power....
Medicine Products: